Chimeric’s (ASX:CHM) CHM 1101 GBM abstract selected for presentation at American Society of Clinical Oncology meeting

Highlights

• CHM 1101, a CAR T cell therapy, is being studied for the treatment of recurrent or progressive glioblastoma (GBM)
• Chimeric's CHM 1101 GBM abstract was picked from more than 6,500 abstract submissions
• It will highlight the cell therapy’s clinical trial design and goals of its Phase 1B trial at the premier oncology meeting, Annual Meeting of the American Society of Clinical Oncology (ASCO)

Australia's Chimeric Therapeutics (ASX: CHM), focused on development of cell therapies for cure of cancer, has announced that the abstract of one of its CAR T therapies would be a part of the presentation at the American Society of Clinical Oncology’s Annual Meeting 2023. Notably, the meeting would take place in Chicago. Illinois (US) in June this year. 

CHM 1101 (CLTX CAR T) and latest development

CHM 1101 is said to be the first and best in class CAR T therapy for use in recurrent or progressive GBM. The research for development of the intellectual property for this therapy was undertaken at the prominent clinical research centre, City of Hope.

Chimeric states that in preclinical trials, CLTX and CLTX CAR T cells were found better than other targeting domains such as EGFR or HER-2 with respect to binding with GBM cells.

The cells make use of chlorotoxin as the component to target the tumour. No off-tumour recognition of normal human cells and tissues was observed when CLTX CAR T cells showed anti-tumour activity (GBM) during pre-clinical models. The therapy is presently in clinical trial (Phase 1A), with initial positive data presented on people treated in first two dose levels.

In the latest development, CHM 1101 abstract would now be in the presentation at June 2023 event of the American Society of Clinical Oncology. The abstract highlights the therapy's clinical trial design and other aspects.

Data source: CHM ASX announcement dated 4 April 2023; Image source: Pixabay.com

About Chimeric Therapeutics

The listed cell therapy company is engaged in discovering and developing promising cell therapies that also include CHM 2101 (CDH17 CAR T), CHM 0201 (CORE-NK platform) besides the above cited therapy. Chimeric is focused on commercialisation of these therapies and their use in treatment of various cancers.

CHM 2101 is the therapy being developed for gastrointestinal and neuroendocrine tumours. CHM 0201 is for solid tumours and blood cancers.

Chimeric is a listed entity, and its ASX shares traded at AU$0.07 at the time of writing on 5 April 2023